# Cannabis Heart Rhythm, Peer-Reviewed at Last: The JACC Data > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-heart-rhythm-jacc-study/ > **Published:** 2026-09-10T07:38:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:06-04:00 > **Clinical Summary:** New research on cannabis heart rhythm: a JACC trial found less cardiac ectopy on cannabis-use days than abstinence days. Here's what it does and doesn't show. --- CED Clinical Relevance #73 Evidence Update: The peer-reviewed data behind last month’s headlines are in, with a caution-flagged editorial attached. Table of Contents - [Cannabis Heart Rhythm: What the Peer-Reviewed JACC Data Actually Show](#Cannabis_Heart_Rhythm_What_the_Peer-Reviewed_JACC_Data_Actually_Show) - [A Small, Real Effect, Not a Verdict on Cannabis and the Heart](#A_Small_Real_Effect_Not_a_Verdict_on_Cannabis_and_the_Heart) - [Eight Ways to Read the Same Heartbeat Data](#Eight_Ways_to_Read_the_Same_Heartbeat_Data)[If you use cannabis regularly and worry about your heart](#If_you_use_cannabis_regularly_and_worry_about_your_heart) - [What changes in how I counsel patients](#What_changes_in_how_I_counsel_patients) - [The obvious alternative explanation](#The_obvious_alternative_explanation) - [Where the methodology has real limits](#Where_the_methodology_has_real_limits) - [How this sits next to what we already knew](#How_this_sits_next_to_what_we_already_knew) - [What this changes in a real visit](#What_this_changes_in_a_real_visit) - [What would actually settle this](#What_would_actually_settle_this) - [What this does and doesn’t say about legality or access](#What_this_does_and_doesn8217t_say_about_legality_or_access) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Cannabis Heart Rhythm: What the Peer-Reviewed JACC Data Actually Show A randomized, crossover trial of 108 habitual cannabis users, now published in the Journal of the American College of Cardiology, found modestly less cardiac ectopy on days participants inhaled cannabis than on days they abstained. The finding is real, the effect size is small, and the accompanying editorial titled “Taking Nothing for Granted” is itself a caution against over-reading it. Here is what the primary data add to what we already told you about this study in August, and what they still don’t answer. Cardiac Safety RCT Evidence Cannabis & Heart Health Arrhythmia Clinical Practice Audience Patients and clinicians navigating cannabis use in cardiovascularly healthy adults Primary Topic Acute cardiac effects of inhaled cannabis: a randomized crossover trial (MARY-JANE) Source [Read the full source (JACC, DOI: 10.1016/j.jacc.2026.07.014)](https://doi.org/10.1016/j.jacc.2026.07.014) Clinical Insight | CED Clinic In August, several outlets reported early results from a UCSF trial suggesting cannabis use days looked no worse, and maybe a little better, for heart rhythm than abstinence days. We covered that early signal ourselves, twice, working from secondhand summaries with no DOI, no trial ID, and no peer review yet attached. That gap is now closed. The full study, *Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose*, by Elias and colleagues at UCSF, is published in the *Journal of the American College of Cardiology*, with exact effect sizes, confidence intervals, and a same-issue editorial urging restraint in how the finding is used. That combination, a real effect cleanly reported with a built-in caution flag from the journal itself, is exactly the kind of evidence worth walking through carefully rather than repeating as a headline. Study Snapshot Study Type Randomized, case-crossover clinical trial (“MARY-JANE”: Marijuana and Acute Risk of Arrhythmia: Joint Abstinence and Exposure) Institution University of California, San Francisco (UCSF) Participants 108 adults (mean age 32±10; 59% women); regular cannabis smokers/vapers with no history of arrhythmia, structural heart disease, or antiarrhythmic use Conditions Tested Premature atrial contractions (PACs) and premature ventricular contractions (PVCs), together “cardiac ectopy” Setting Ambulatory, 14-day at-home monitoring (continuous ECG patch, continuous glucose monitor, fitness tracker); 713 person-days randomized to inhaled cannabis vs. 616 days to abstinence Outcomes Measured Daily ectopic-beat frequency (primary); mean glucose, step counts, sleep duration (secondary) Key Finding 9% relative reduction in daily ectopic beats on cannabis-inhalation days vs. abstinence days (rate ratio [RR] 0.91; 95% CI 0.85–0.98; P=0.02), driven by a 10% reduction in PACs (RR 0.90; 95% CI 0.82–0.97; P=0.012); PVCs unchanged. Each individual inhalation was associated with a further 2% reduction in ectopic beats (RR 0.98; 95% CI 0.97–0.99; P=0.043). Secondary Finding No significant differences in glucose levels, step counts, or sleep duration between cannabis and abstinence days Trial Registration [NCT06021613](https://clinicaltrials.gov/study/NCT06021613), completed May 2025; excluded anyone with a history of atrial fibrillation, heart failure, congenital heart disease, an ICD/pacemaker, a prior cardiac ablation, antiarrhythmic drug use, or insulin use Journal / Publication Journal of the American College of Cardiology (JACC): research article published July 30, 2026, with an accompanying editorial published August 27, 2026 PMID / DOI Research article: PMID 42584385 / [DOI 10.1016/j.jacc.2026.07.014](https://doi.org/10.1016/j.jacc.2026.07.014). Editorial (“Taking Nothing for Granted”): PMID 42714360 / [DOI 10.1016/j.jacc.2026.08.009](https://doi.org/10.1016/j.jacc.2026.08.009). Why This Matters Most of what we know about cannabis and heart rhythm comes from observational data, the kind that can’t separate cause from coincidence. This trial is different: participants served as their own controls, randomly assigned to use or abstain on different days over two weeks, wearing a continuous heart monitor the whole time. That design is what lets us say the 9% reduction in ectopic beats is a real, measured association within this study, not just a pattern someone noticed after the fact. For patients who already worry that their cannabis use is causing palpitations, that is a genuinely useful data point in a cardiovascularly healthy population like the one studied here, an increase in ectopy on cannabis days is not what the best current randomized evidence shows. Where This Paper Deserves Skepticism The authors’ own discussion, and the entire premise of the accompanying editorial, is a caution against reading this as “cannabis protects the heart.” A crossover trial in habitual users compares cannabis days to abstinence days within the same person. The more parsimonious explanation for fewer ectopic beats on use days is that abstinence itself provoked more ectopy, plausibly through withdrawal-related autonomic or sympathetic activation in people accustomed to regular use, not that inhaled cannabis has a protective cardiac effect in any general sense. The authors are explicit about this: they describe “potential withdrawal effects, moderate adherence, and co-intervention” as limiting factors on causal interpretation. Adherence to the randomized schedule was imperfect. And the population was pre-selected to be low risk: no arrhythmia history, no antiarrhythmic drugs, no implanted devices, no insulin use. None of that makes the result wrong; it makes it narrow, and narrow results get misread the moment they leave the paper. How This Fits With the Broader Clinical Conversation This finding does not contradict the separate, larger body of observational evidence linking heavier, longer-term cannabis use to higher rates of atrial fibrillation and cardiovascular events. Those studies are asking a different question over a different timescale: cumulative, chronic exposure and structural or vascular risk, while MARY-JANE asked about acute, day-to-day rhythm effects in people who were already regular users and already cardiovascularly healthy. Both things can be true at once: acute inhalation may not provoke more ectopy on the day of use in a low-risk habitual user, while sustained heavy use over years still carries measurable cardiovascular risk in the population as a whole. Patients, and the headlines built for them, tend to flatten that distinction into a single verdict. It is worth not doing that here. Evidence Interpretation Guide ## A Small, Real Effect, Not a Verdict on Cannabis and the Heart The Research Question Does acute inhaled cannabis change how often habitual, cardiovascularly healthy users have premature heartbeats, compared with days they abstain? The Patient Question “Is my cannabis use giving me palpitations, or could quitting be what’s giving me palpitations?” The Bottom Line In healthy habitual users, ectopy was modestly lower on cannabis days than on abstinence days, most consistent with a withdrawal-related effect of abstinence, not proof that cannabis protects the heart. CED Perspective Lens ## Eight Ways to Read the Same Heartbeat Data A single randomized trial can support very different reactions depending on who’s asking. Pick a lens. Lens Overview The MARY-JANE trial found a small, statistically real reduction in ectopic heartbeats on cannabis-inhalation days versus abstinence days, in healthy habitual users, with a same-issue editorial urging caution about the interpretation. #### If you use cannabis regularly and worry about your heart This trial does not show that your cannabis use is causing extra palpitations. In fact, in people just like you, regular users with no history of heart disease, the days they used cannabis had slightly fewer, not more, extra heartbeats than the days they abstained. That is reassuring at the level of this specific question, but it is not permission to treat cannabis as heart-protective, and it says nothing about what happens over years of use, or about anyone with an existing heart rhythm problem; those patients were not in this study. Lens takeaway A real but narrow reassurance for healthy, regular users, not a green light, and not relevant if you already have a heart rhythm condition. #### What changes in how I counsel patients When a cardiovascularly healthy patient reports palpitations and also uses cannabis regularly, this trial is a reason not to reflexively attribute the symptom to their current use pattern: the best acute randomized data available point the other way. It is a much weaker basis for reassuring a patient with known arrhythmia, structural heart disease, or antiarrhythmic therapy, since that population was excluded by design. It’s also worth raising proactively with patients who are tapering or quitting cannabis for other clinical reasons: if abstinence itself is associated with more ectopy in habitual users, that’s a symptom worth anticipating and normalizing during a taper, not a reason to reverse course. Lens takeaway Useful for reassurance in low-risk patients and for anticipatory guidance during cessation; not generalizable to patients with cardiac disease. #### The obvious alternative explanation This is a within-person comparison of use days to abstinence days in people who use cannabis regularly. The cleanest reading isn’t “cannabis reduces ectopy”; it’s “abstinence, in habitual users, is associated with more ectopy,” which is a withdrawal story, not a cardioprotection story. The authors say as much themselves. A trial in cannabis-naive participants, or one comparing users to true non-users, would be needed to separate “cannabis is good for rhythm” from “not having cannabis you’re used to is bad for rhythm.” This study can’t do that, and doesn’t claim to. Lens takeaway Read this as evidence about withdrawal, not evidence about cannabis’s cardiac benefit. #### Where the methodology has real limits Strengths first: randomized assignment of use/abstain days, continuous ECG monitoring rather than self-report, and a reasonably sized sample (108 participants, 1,329 person-days) for this kind of ambulatory trial. That’s meaningfully better evidence than the observational literature this field usually runs on. Weaknesses: adherence to assignment was “imperfect,” which dilutes any true effect in either direction; the population was pre-screened to be low cardiac risk, so results don’t extend to higher-risk patients; and “co-intervention” (the authors’ own term) means other behaviors tied to use or abstinence days weren’t fully controlled. The effect sizes, while statistically significant, are small: a 9-10% relative reduction is not a large clinical signal. Lens takeaway Solid design for the question it asks; a modest effect size and real adherence/generalizability limits keep this from being definitive. #### How this sits next to what we already knew Most existing cannabis-cardiovascular literature is observational and points toward increased long-term risk: higher rates of atrial fibrillation and cardiovascular events with heavier, sustained use. This trial doesn’t overturn that; it asks a narrower, acute question in a different population using a stronger design. It’s also a partial correction to how this same finding was covered here in August, before the peer-reviewed paper existed; those pieces worked from secondhand news summaries; this one works from the actual data, the actual confidence intervals, and an editorial the earlier coverage couldn’t have seen. Lens takeaway Complements, rather than contradicts, the longer-term observational risk literature: different question, different timescale. #### What this changes in a real visit For a healthy adult with no arrhythmia history who mentions occasional palpitations and regular cannabis use, this trial supports looking elsewhere first: caffeine, stress, sleep, alcohol, thyroid, rather than assuming cannabis is the driver, while still taking any new or worsening palpitation seriously enough to work up appropriately. For anyone with known arrhythmia, structural heart disease, an implanted device, or on antiarrhythmic medication, this study says nothing either way: that population was specifically excluded, and existing cardiac-risk guidance for cannabis use should stand. Lens takeaway Changes the differential in low-risk patients; changes nothing for patients with existing cardiac disease. #### What would actually settle this A trial comparing habitual users to matched non-users, or one that isolates withdrawal physiology directly (heart-rate variability, catecholamine levels) during abstinence days, would help separate “cannabis effect” from “withdrawal effect.” Longer follow-up beyond 14 days would also clarify whether this acute pattern has any bearing on the chronic-risk signal seen in observational cohorts. Extending a similar design to patients with existing arrhythmias, under appropriate safety monitoring, is the study clinicians actually need before this evidence can inform higher-risk patients. Lens takeaway The next useful trial isolates withdrawal physiology and extends the population to cardiac patients; this one deliberately didn’t. #### What this does and doesn’t say about legality or access This is a clinical-physiology finding, not a policy argument. It doesn’t speak to legalization, scheduling, or access debates, and treating it as ammunition for either side of those debates overstates what a single small trial in low-risk volunteers can support. Its actual policy relevance is narrower and more useful: it’s an argument for funding more randomized cannabis research generally, since this kind of prospective, monitored design produces cleaner answers than the observational data policymakers usually have to work with. Lens takeaway A case for more trials like this one, not a data point for either side of the legalization debate. Dr. Caplan’s Take After more than 400,000 patient encounters in [cannabis medicine](https://cedclinic.com/cbd-gummies-fatty-liver-evidence-practical-considerations/), the question I hear most about the heart isn’t “will this hurt me long-term”; it’s “why do I feel palpitations, and is it the cannabis.” This trial is a genuinely useful data point for that specific, common conversation, in patients who are otherwise healthy: it does not support blaming acute use for new ectopy, and it flags that quitting itself may come with a rhythm-related adjustment worth naming in advance. What it changes nothing about is the patient in front of me with known arrhythmia, a device, or antiarrhythmic medication: this trial simply doesn’t apply for that patient, because it was designed not to include them. The editorial’s title is the right instruction here: take nothing for granted, in either direction. What a Careful Reader Should Take Away A well-designed randomized trial found a small, real reduction in ectopic heartbeats on cannabis-use days versus abstinence days, in healthy habitual users, most plausibly reflecting a withdrawal effect of abstinence rather than a cardioprotective effect of cannabis. The finding is reassuring for a narrow, common clinical question and irrelevant to patients with existing heart rhythm disease, who were excluded from the trial entirely. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis & Cardiac Ectopy: What the Evidence Shows](https://cedclinic.com/cannabis-users-less-likely-to-have-cardiac-ectopy-on-days-they-partake-tctmd-com/) Our first look at this trial, written from early conference/news coverage before the peer-reviewed paper existed. [Read the early coverage](https://cedclinic.com/cannabis-users-less-likely-to-have-cardiac-ectopy-on-days-they-partake-tctmd-com/) [Cannabis Reduces Ectopic Heartbeats: Early Trial Data](https://cedclinic.com/inhaled-cannabis-reduces-number-of-daily-ectopic-heart-beats/) Our second pass at the same early signal, published two days after the first. [See the earlier post](https://cedclinic.com/inhaled-cannabis-reduces-number-of-daily-ectopic-heart-beats/) [Your Heart on Weed: 7 Facts About Cannabis Cardiovascular Risk](https://cedclinic.com/cannabis-cardiovascular-risk-review/) The broader, longer-term cardiovascular risk picture this single trial does not overturn. [Get the full picture](https://cedclinic.com/cannabis-cardiovascular-risk-review/) ## Frequently Asked Questions What did the new JACC study actually find about cannabis and heart rhythm? In a randomized crossover trial of 108 habitual cannabis users, days on which participants inhaled cannabis showed 9% fewer ectopic heartbeats (extra beats) than days they abstained, driven mainly by a 10% reduction in premature atrial contractions. Premature ventricular contractions did not change significantly. Does this mean cannabis is good for the heart? No. The study’s own authors and the accompanying editorial caution against that reading. The more likely explanation is that abstinence in habitual users provoked more ectopy through a withdrawal-related effect, not that cannabis itself protects cardiac rhythm. Who was studied, and who wasn’t? The trial enrolled 108 healthy adults who were already regular cannabis smokers or vapers, with no history of arrhythmia, structural heart disease, implanted cardiac devices, prior ablation, antiarrhythmic drug use, or insulin use. Anyone with those conditions was excluded, so the results don’t extend to them. What is “cardiac ectopy” and why does it matter? Cardiac ectopy refers to extra or early heartbeats originating outside the heart’s normal pacemaker rhythm: premature atrial contractions (PACs) and premature ventricular contractions (PVCs). Most ectopic beats are benign, but frequent ectopy can sometimes signal or contribute to more serious rhythm problems, which is why researchers and clinicians track it. Why did ectopy go down on cannabis days instead of up? The leading explanation is that abstinence itself, in people accustomed to regular use, may increase sympathetic or autonomic nervous system activity as a withdrawal effect, which could increase ectopic beats. On that reading, cannabis days aren’t “protective”; abstinence days are simply harder on the heart’s rhythm in habitual users. How does this fit with studies linking cannabis to atrial fibrillation and heart attack risk? Those studies are observational and look at cumulative, long-term use and chronic cardiovascular risk. This trial asked a narrower question: acute, day-to-day rhythm effects in already-healthy regular users, using a stronger randomized design. The two bodies of evidence are not in direct conflict; they’re answering different questions on different timescales. Does this apply to patients with existing heart disease or arrhythmias? No. Patients with a history of atrial fibrillation, heart failure, congenital heart disease, an implanted cardiac device, a prior ablation, or antiarrhythmic medication use were excluded from this trial by design. Existing cardiac-risk guidance for those patients is unchanged by this study. What did the accompanying JACC editorial caution about? The editorial, titled “Taking Nothing for Granted,” was published in the same journal alongside the study specifically to urge readers not to over-interpret the finding as evidence that cannabis benefits cardiac rhythm, given the trial’s crossover design, imperfect adherence, and narrowly selected low-risk population. What should patients who are trying to reduce or quit cannabis know from this study? If this trial’s pattern reflects a withdrawal effect, it suggests some habitual users may notice more palpitation-type symptoms during a period of abstinence. That’s worth discussing with a clinician in advance of a taper, as an expected and typically benign adjustment rather than a new medical problem. What would make this evidence stronger? A trial comparing habitual users to matched non-users, direct measurement of withdrawal physiology (such as heart-rate variability or catecholamine levels) during abstinence days, longer follow-up, and an appropriately monitored extension of this design to patients with existing arrhythmias would all clarify what this initial signal actually represents. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).